VX-150
Sponsors
Vertex Pharmaceuticals Incorporated
Conditions
Acute PainOsteoarthritisPainPijn.
Pain.Small Fiber Neuropathypijn
pain
Phase 1
Phase 2
A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee
CompletedNCT02660424
Start: 2015-12-31End: 2016-09-30Updated: 2020-09-30
A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
CompletedNCT03206749
Start: 2017-06-29End: 2017-12-08Updated: 2021-02-03
A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
CompletedNCT03304522
Start: 2017-09-20End: 2018-11-08Updated: 2021-11-15
A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
CompletedNCT03764072
Start: 2018-12-12End: 2019-01-25Updated: 2022-02-09
Unknown Phase
A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study evaluating safety and pharmacokinetics of VX-150 including an assessment of the effect of food on the pharmacokinetics of VX-150 in healthy adult subjects.
Active, not recruitingNL-OMON41908
Start: 2015-01-28Target: 96Updated: 2024-02-28
A phase 1, randomized, double-blind, placebo-controlled study evaluating the pharmacokinetics of capsule and tablet formulations of VX-150, including the effects of food and milk, the relative bioavailability of the tablet formulation, and the drug-drug interaction between VX-150 and Midazolam, in healthy adults
Active, not recruitingNL-OMON45544
Start: 2017-01-27Target: 40Updated: 2024-02-28